Responses
Clinical/translational cancer immunotherapy
Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Compose a Response to This Article
Other responses
No responses have been published for this article.
